Foretinib (BioDeep_00000858836)
代谢物信息卡片
Foretinib (GSK1363089)
化学式: C34H34F2N4O6 (632.2446288000001)
中文名称: Foretinib
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: COC1=CC2=C(C=CN=C2C=C1OCCCN3CCOCC3)OC4=C(C=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F)F
InChI: InChI=1S/C34H34F2N4O6/c1-43-30-20-25-27(21-31(30)45-16-2-13-40-14-17-44-18-15-40)37-12-9-28(25)46-29-8-7-24(19-26(29)36)39-33(42)34(10-11-34)32(41)38-23-5-3-22(35)4-6-23/h3-9,12,19-21H,2,10-11,13-18H2,1H3,(H,38,41)(H,39,42)
描述信息
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:91418
- KEGGdrug: D09618
- PubChem: 42642645
- DrugBank: DB12307
- ChEMBL: CHEMBL1230609
- CAS: 937176-80-2
- CAS: 849217-64-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Xiwei Ji, Xiangrui Meng, Qingfeng He, Xiaoqiang Xiang, Yufei Shi, Xiao Zhu. Foretinib Is Effective against Triple-Negative Breast Cancer Cells MDA-MB-231 In Vitro and In Vivo by Down-Regulating p-MET/HGF Signaling.
International journal of molecular sciences.
2023 Jan; 24(1):. doi:
10.3390/ijms24010757. [PMID: 36614199] - Hany W Darwish, Ahmed H Bakheit, Zahi S Al-Anazi, Nasser S Al-Shakliah, Abdullah M Al-Hossaini, Ibrahim A Naguib, Ibrahim A Darwish. Response surface methodology for optimization of micellar-enhanced spectrofluorimetric method for assay of foretinib in bulk powder and human urine.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2021 Aug; 257(?):119811. doi:
10.1016/j.saa.2021.119811. [PMID: 33892248] - Hany W Darwish, Ahmed H Bakheit, Nasser S Al-Shakliah, Ibrahim A Darwish. Development of innovative artificial neural networks for simultaneous determination of lapatinib and foretinib in human urine by micellar enhanced synchronous spectrofluorimetry.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.
2020 Sep; 238(?):118438. doi:
10.1016/j.saa.2020.118438. [PMID: 32388416] - Nan Guo, Aiying Zhang, Hui Zhuang, Changzhen Zhang. LC-MS/MS assay for the quantification of foretinib in rat plasma and its application to preclinical pharmacokinetic study.
Biomedical chromatography : BMC.
2020 Aug; 34(8):e4862. doi:
10.1002/bmc.4862. [PMID: 32307722] - Zhi Xu, Shi-Jia Zhao, Yi Liu. 1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
European journal of medicinal chemistry.
2019 Dec; 183(?):111700. doi:
10.1016/j.ejmech.2019.111700. [PMID: 31546197] - Daniel A Polasky, Sugyan M Dixit, Daniel D Vallejo, Kathryn D Kulju, Brandon T Ruotolo. An Algorithm for Building Multi-State Classifiers Based on Collision-Induced Unfolding Data.
Analytical chemistry.
2019 08; 91(16):10407-10412. doi:
10.1021/acs.analchem.9b02650. [PMID: 31310505] - Khurshed Bozorov, Jiangyu Zhao, Haji A Aisa. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.
Bioorganic & medicinal chemistry.
2019 08; 27(16):3511-3531. doi:
10.1016/j.bmc.2019.07.005. [PMID: 31300317] - Mohamed W Attwa, Adnan A Kadi, Hany W Darwish, Sawsan M Amer, Haitham Alrabiah. A reliable and stable method for the determination of foretinib in human plasma by LC-MS/MS: Application to metabolic stability investigation and excretion rate.
European journal of mass spectrometry (Chichester, England).
2018 Aug; 24(4):344-351. doi:
10.1177/1469066718768327. [PMID: 29629565] - Thomas C C Yau, Riccardo Lencioni, Wattana Sukeepaisarnjaroen, Yee Chao, Chia-Jui Yen, Wirote Lausoontornsiri, Pei-Jer Chen, Theeranun Sanpajit, Aaron Camp, Donna S Cox, Robert C Gagnon, Yuan Liu, Kristen E Raffensperger, Diptee A Kulkarni, Howard Kallender, Lone Harild Ottesen, Ronnie T P Poon, Donald P Bottaro. A Phase I/II Multicenter Study of Single-Agent Foretinib as First-Line Therapy in Patients with Advanced Hepatocellular Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017 May; 23(10):2405-2413. doi:
10.1158/1078-0432.ccr-16-1789. [PMID: 27821605] - Giulia Courthod, Marcello Tucci, Massimo Di Maio, Giorgio V Scagliotti. Papillary renal cell carcinoma: A review of the current therapeutic landscape.
Critical reviews in oncology/hematology.
2015 Oct; 96(1):100-12. doi:
10.1016/j.critrevonc.2015.05.008. [PMID: 26052049] - Geoffrey I Shapiro, Stewart McCallum, Laurel M Adams, Laurie Sherman, Steve Weller, Suzanne Swann, Harold Keer, Dale Miles, Thomas Müller, Patricia Lorusso. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
Investigational new drugs.
2013 Jun; 31(3):742-50. doi:
10.1007/s10637-012-9881-z. [PMID: 23054208] - Theodore F Logan. Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.
Current oncology reports.
2013 Apr; 15(2):83-90. doi:
10.1007/s11912-013-0299-3. [PMID: 23408121] - Toni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, Theodore F Logan, Andrea L Harzstark, Ronald M Bukowski, Brian I Rini, Sandy Srinivas, Mark N Stein, Laurel M Adams, Lone H Ottesen, Kevin H Laubscher, Laurie Sherman, David F McDermott, Naomi B Haas, Keith T Flaherty, Robert Ross, Peter Eisenberg, Paul S Meltzer, Maria J Merino, Donald P Bottaro, W Marston Linehan, Ramaprasad Srinivasan. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2013 Jan; 31(2):181-6. doi:
10.1200/jco.2012.43.3383. [PMID: 23213094] - Edwin M Posadas, Robert A Figlin. Understanding the role of MET kinase in cancer therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2013 Jan; 31(2):169-70. doi:
10.1200/jco.2012.46.7738. [PMID: 23213104] - Manish A Shah, Zev A Wainberg, Daniel V T Catenacci, Howard S Hochster, James Ford, Pamela Kunz, Fa-Chyi Lee, Howard Kallender, Fabiola Cecchi, Daniel C Rabe, Harold Keer, Anne-Marie Martin, Yuan Liu, Robert Gagnon, Peter Bonate, Li Liu, Tona Gilmer, Donald P Bottaro. Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
PloS one.
2013; 8(3):e54014. doi:
10.1371/journal.pone.0054014. [PMID: 23516391] - Aung Naing, Razelle Kurzrock, Laurel M Adams, Joseph F Kleha, Kevin H Laubscher, Peter L Bonate, Steven Weller, Colleen Fitzgerald, Yanmei Xu, Patricia M LoRusso. A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
Investigational new drugs.
2012 Feb; 30(1):327-34. doi:
10.1007/s10637-010-9536-x. [PMID: 20842406] - Joseph Paul Eder, Geoffrey I Shapiro, Leonard J Appleman, Andrew X Zhu, Dale Miles, Harold Keer, Belinda Cancilla, Felix Chu, Suzanne Hitchcock-Bryan, Laurie Sherman, Stewart McCallum, Elisabeth I Heath, Scott A Boerner, Patricia M LoRusso. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010 Jul; 16(13):3507-16. doi:
10.1158/1078-0432.ccr-10-0574. [PMID: 20472683]